Iambic Therapeutics, Inc. Common Stock (IAM) Stock Price & Analysis
Iambic Therapeutics, Inc. Common Stock (IAM) closed at USD 18.91 on Thursday, October 15, 2026, up 18.19% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 16; the Oct 15, 2026 session ranged USD 16.15–19.7 on volume of 2,006,424 shares. Market capitalization is $896.35M, with a 52-week range of USD 16.15–19.7 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IAM.md
Key facts (IAM)
- Analysts: None.
- Total return with dividends: 5Y +0.0% vs S&P 500 +85.1%.
Analysts (IAM)
Consensus None.
Total return (dividends reinvested) (IAM)
| 5Y (from 2026-10-12) | |
|---|---|
| Total return | +0.0% |
| S&P 500 (SPY) | +85.1% |
| Per year | — |
| Volatility (annualized) | 0.0% |
| Max drawdown | +0.0% (→) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 18.91 |
|---|---|
| Change | ▲ 18.19% (up) |
| Previous Close | USD 16 |
| Open | USD 16.15 |
| Day Range | USD 16.15 – 19.7 |
| 52-Week Range | USD 16.15 – 19.7 |
| Volume | 2,006,424 shares |
| Market Cap | $896.35M |
| Exchange | NMS |
Analyst Ratings (IAM)
Wall Street analysts rate IAM "None", per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | None |
|---|
Earnings (IAM)
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (IAM)
| Total Revenue | $18.25M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +224.70% |
| Gross Margin | +0.00% |
| Operating Margin | -419.59% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.03 |
| Current Ratio | 4.59 |
| Total Cash | $207.88M |
| Total Debt | $5.23M |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Ownership (IAM)
| Shares Outstanding | 47.40M |
|---|---|
| Float | 4.17M |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (IAM)
Iambic Therapeutics, Inc. Common Stock is led by Thomas Miller (age 46), Co-Founder, CEO, Secretary & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| Co-Founder, CEO, Secretary & Director | Thomas Miller (age 46) |
|---|---|
| Co-Founder, CTO & Director | Frederick Manby (age 53) |
| Chief Corporate Development Officer & CFO | Michael Secora (age 42) |
| Chief Scientific Officer | Peter Olson (age 51) |
| Senior Vice President of Machine Learning | Matt Welborn |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt